This study is a phase 2/3 clinical trial to evaluate the efficacy and safety of SHR-1703 in patients with EGPA.
Male or female subjects age 18 years or older;
Diagnosed with EGPA for at least 6 months;
History of relapsing or refractory EGPA；
Stable dose of oral prednisone of ≥7.5 mg/day (but not >50 mg/day) for at least 4 weeks prior to randomization;
Subjects with other eosinophilic-related diseases;
Diagnosed with granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA).
Life-threatening EGPA within 3 months prior to randomization;
Malignancy history within 5 years prior to randomization;